Edwards Lifesciences Corporation EW
Edwards Lifesciences is executing well — FY2025 revenue grew 11.55% to $6.07B with a 22% FCF margin and a fortress balance sheet of $705M debt against $10.34B equity — but the stock trades at 53.0x earnings (a 64% premium to the peer median of 32.3x) and 8.2x sales (113% above the 3.8x peer median), pricing in near-flawless execution with little margin of safety. Positive technical momentum (last close $92.28 above both the 50-day MA of $88.87 and 200-day MA of $84.58 with a positive MACD histogram) and BlackRock's newly disclosed ~10.21% stake provide near-term support, but a GuruFocus DCF pegs intrinsic value at $53 versus the current price, underscoring the stretched valuation.
The growth narrative is intact; the valuation is the risk.
What could go wrong
- Premium valuation compression. At 53.0x P/E and 8.2x P/S — 64% and 113% above peer medians respectively — any deceleration in revenue growth or margin pressure could trigger a sharp multiple contraction.
- EPS optics from 2024 one-time gain. FY2024 net income of $4.17B far exceeded operating income of $1.38B, inflating EPS to $6.97; FY2025 EPS normalized to $1.83, and investors misreading this as deterioration could pressure sentiment.
- Competitive intensity in structural heart. TAVR and mitral/tricuspid repair markets are attracting intensified competition; share loss or pricing pressure would directly threaten the 78.13% gross margin and 26.97% operating margin.
- Insider selling pattern. Over the trailing 24 months, insiders recorded 128 dispositions versus 84 acquisitions; recent transactions are predominantly option-exercise-then-sell patterns, offering no bullish insider signal.
What would change my mind
Where this comes from: FMP annual fundamentals + derived_metrics, fiscal year ended 2025-12-31 · peer_relative composite · technicals as of 2026-08-19 · news article, Defense World, published 2026-08-19. Orin's read on EW; not advice.
Twelve months actual closes to 2026-09-24 · actual filings
50-day average 200-day average · volume below
On file
All EW filingsLargest holders · 13F Q2 2026
Money flow| Filer | Position | Of fund |
|---|---|---|
| Vanguard Capital Management | $3.4B | 0.1% of fund |
| Vanguard Portfolio Management | $2.4B | 0.1% of fund |
| State Street | $2.4B | 0.1% of fund |
| Jpmorgan Chase & | $2.1B | 0.1% of fund |
| Wellington Management Group Llp | $1.5B | 0.3% of fund |
| Geode Capital Management | $1.4B | 0.1% of fund |
98 filers · quarter ended Q2 2026 · positions, not flows
Insiders, last 24 months: 226 Form 4 filings, net $17.7M. Of the 50 on hand, 0 were open-market purchases and 17 sales— the rest are grants, option exercises and tax withholding.
Ask Orin about EW
Orin answers questions about EW from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.
Start 3 free days →Where it trades
| Metric | Now | Own median | Sector |
|---|---|---|---|
| P/E | 49.3× | 33.0× | 26.4× |
| EV/EBITDA | 30.6× | 29.8× | — |
| P/S | 7.58× | 8.58× | — |
| P/B | 4.7× | 7.0× | — |
Its P/E sits 80th percentile of its own last 5 years (+0.97σ from its own mean).
16.1%
free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $1.3B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.
What Wall Street published
$102
$85 – $110 · +17% against today's price
- 33 buy or overweight
- 16 hold
- 0 underweight or sell
The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.
Against the companies it is compared to
| Company | Market cap | P/E | EV/EBITDA | Gross | Net | ROE |
|---|---|---|---|---|---|---|
| EWEdwards Lifesciences Corporation | $49B | 49.3× | 30.6× | 78.0% | 15.4% | 10% |
| AAgilent Technologies, Inc. | $49B | 34.0× | 25.9× | 53.7% | 19.5% | 20% |
| BDXBecton, Dickinson and Company | $49B | 54.0× | 16.8× | 46.1% | 4.5% | 4% |
| CAHCardinal Health, Inc. | $52B | 30.6× | 16.5× | 3.8% | 0.7% | -60% |
| DXCMDexCom, Inc. | $33B | 33.8× | 21.4× | 62.5% | 20.1% | 36% |
| STESTERIS plc | $20B | 25.5× | 12.1× | 44.4% | 13.3% | 11% |
The median is of the 5 peers listed above and nothing else — check it against the column. This company trades 45.9% above it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.
What it has traded at
What its sector has traded at
Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.
Discounted cash flow
| Model | Fair value | Against | Computed |
|---|---|---|---|
| Standard DCF | $62 | $86.11 · −28% | 2026-06-10 |
| Levered DCF | $46 | $86.11 · −46% | 2026-06-10 |
The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.
Every estimate on one scale
The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.